Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Canagliflozin Hemihydrate: Precision SGLT2 Inhibitor for ...

    2025-10-18

    Canagliflozin Hemihydrate: A Precision SGLT2 Inhibitor for Glucose Metabolism Research

    Principle Overview: Small Molecule SGLT2 Inhibitor in Diabetes Research

    As metabolic disorder research advances, the demand for pathway-specific tools has never been greater. Canagliflozin (hemihydrate) (SKU: C6434) emerges as a gold-standard small molecule SGLT2 inhibitor, purpose-engineered to interrogate renal glucose reabsorption and facilitate translational diabetes mellitus research. Characterized by a molecular weight of 453.52 and a purity of ≥98% (validated by HPLC and NMR), Canagliflozin hemihydrate offers high solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), while remaining insoluble in water—enabling versatile deployment in diverse experimental models.

    Unlike broad-spectrum kinase inhibitors or compounds with off-target effects, Canagliflozin’s mechanism centers on sodium-glucose co-transporter 2 (SGLT2) inhibition. This action blocks glucose reabsorption in the proximal renal tubule, leading to increased glucose excretion and effective modulation of systemic glucose homeostasis. Its precise targeting distinguishes it from compounds screened for mTOR inhibition, such as those evaluated in the recent GeroScience yeast-based drug discovery platform, where Canagliflozin demonstrated no mTOR inhibitory activity, thereby affirming its pathway specificity and minimizing off-target confounds in metabolic studies.

    Step-by-Step Workflow: Optimizing Experimental Protocols with Canagliflozin Hemihydrate

    1. Compound Preparation and Solubilization

    • Stock Solution: Dissolve Canagliflozin hemihydrate in DMSO or ethanol to a concentration up to 83.4 mg/mL (DMSO) or 40.2 mg/mL (ethanol). Vortex to ensure complete dissolution.
    • Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw cycles. Store at -20°C; avoid long-term storage of diluted solutions to preserve activity.
    • Working Solution: Dilute stock immediately before use in your desired experimental buffer/media, ensuring the final DMSO/ethanol concentration does not exceed cytotoxic thresholds (usually ≤0.1–0.5% v/v in cell-based assays).

    2. In Vitro Assays: Renal Glucose Reabsorption and Glucose Uptake Studies

    • Cell Line Selection: Use HK-2 (human proximal tubule) or other SGLT2-expressing cell lines for direct mechanistic studies.
    • Treatment Regimen: Expose cells to a range of Canagliflozin concentrations (e.g., 10 nM–10 µM) in the presence of a glucose substrate. Incubate for 1–24 hours depending on assay sensitivity.
    • Readout: Quantify glucose uptake using fluorescent or colorimetric glucose analogs (e.g., 2-NBDG, glucose oxidase assays). Normalize to protein content or cell number.
    • Controls: Include untreated, vehicle, and positive control (e.g., dapagliflozin or phlorizin) groups to verify specificity and dynamic range.

    3. In Vivo Models: Glucose Homeostasis and Diabetes Mellitus Research

    • Dosing: Administer Canagliflozin hemihydrate via oral gavage or dietary admixture. Typical dosing in rodent models ranges from 1–10 mg/kg/day, titrated based on pilot pharmacokinetic data and desired glycemic modulation.
    • Endpoints: Measure fasting and postprandial blood glucose, urinary glucose excretion, body weight, and insulin sensitivity (e.g., glucose/insulin tolerance tests).
    • Sample Handling: Collect serum and urine at standardized timepoints for downstream metabolomics, renal function markers, and pathway analysis.

    4. Data Analysis and Validation

    • Compare treated versus control groups using appropriate statistical tests (e.g., ANOVA, t-test). Integrate dose-response modeling to determine IC50 or maximal efficacy.
    • Correlate observed effects with SGLT2 expression (via qPCR or Western blot) to reinforce mechanistic linkage.

    Advanced Applications and Comparative Advantages

    Canagliflozin hemihydrate’s robust selectivity for SGLT2 inhibition positions it as an indispensable tool for metabolic disorder research, especially when dissecting the glucose homeostasis pathway and modeling renal glucose reabsorption inhibition. Its advantages are multifaceted:

    • Pathway Precision: By acting exclusively on SGLT2, Canagliflozin minimizes off-target impacts on other glucose transporters or kinases. This was confirmed in the GeroScience mTOR inhibitor discovery system, which found no evidence of TOR inhibition by Canagliflozin, in contrast to compounds like rapamycin or Torin1.
    • High Purity and Batch Consistency: With ≥98% purity and rigorous QC, experimental reproducibility is assured—critical for translational and preclinical studies.
    • Superior Solubility: High solubility in DMSO and ethanol (up to 83.4 mg/mL and 40.2 mg/mL, respectively) allows for precise titration and flexibility in dosing regimens.
    • Enabling Advanced Models: Canagliflozin hemihydrate is routinely used in complex models such as diabetic nephropathy, metabolic syndrome, and insulin resistance, facilitating mechanistic studies beyond basic glucose-lowering effects.

    These features set Canagliflozin apart from broader-acting molecules or those with overlapping mTOR or efflux pathway activity. For example, in contrast to the high-sensitivity yeast-based drug discovery platform (Breen et al., 2025), which is optimized for mTOR pathway interrogation, Canagliflozin enables focused SGLT2 pathway research without confounding off-target effects.

    For a more applied perspective, "Applied Workflows with Canagliflozin Hemihydrate in Glucose Metabolism Research" complements this protocol by offering hands-on guidance for troubleshooting and experimental design, while "Canagliflozin Hemihydrate in SGLT2 Inhibitor Research: Mechanistic Insights" provides a deep dive into mechanistic validation, contrasting Canagliflozin’s action with mTOR-targeting compounds and reinforcing its unique research value.

    Troubleshooting and Optimization: Maximizing Data Quality

    • Solubility Concerns: If precipitation occurs upon dilution, pre-warm solvents to 37°C and add stock slowly to the media with continuous mixing. For aqueous applications, consider formulating with cyclodextrins or using co-solvent systems as described in published protocols (see advanced workflow tips).
    • Compound Stability: Use freshly prepared solutions and avoid storing diluted aliquots for more than 24 hours at 4°C, as degradation or loss of potency may occur. Always store dry powder at -20°C, protected from light and moisture.
    • Assay Interference: Monitor vehicle concentrations closely to eliminate DMSO or ethanol cytotoxicity. Validate that observed effects are due to SGLT2 inhibition by including specific rescue experiments or using SGLT2-knockdown controls.
    • Batch Variation: Source from reputable suppliers and confirm batch purity with in-house LC-MS or HPLC analysis if possible, particularly for high-impact studies or publications.
    • Data Interpretation: When unexpected results arise (e.g., lack of glucose-lowering effect), verify cell line or animal model SGLT2 expression, compound solubility, and dosing accuracy. Cross-reference with positive control inhibitors to ensure assay responsiveness.

    For comprehensive troubleshooting and optimization tactics—including advanced solvent systems and cross-validation strategies—see the guide "Canagliflozin Hemihydrate: Precision Tool for Dissecting Glucose Reabsorption", which extends on these methods for complex experimental models.

    Future Outlook: Expanding the Frontiers of SGLT2 Inhibitor Research

    The utility of Canagliflozin hemihydrate in metabolic disorder research continues to expand, driven by its reliability, pathway selectivity, and translational relevance. Upcoming directions include:

    • Integration with Omics Platforms: Combining SGLT2 inhibition with transcriptomics, proteomics, and metabolomics for systems-level pathway mapping.
    • Next-Generation Disease Models: Employing Canagliflozin in organ-on-chip, humanized mouse, and 3D culture systems to recapitulate renal and metabolic physiology more faithfully.
    • Comparative Pathway Dissection: Positioning Canagliflozin alongside novel SGLT2 inhibitors and mTOR-targeting compounds to clarify mechanistic boundaries and therapeutic synergies; for example, "Next-Generation SGLT2 Inhibitor Research" explores such frontiers.
    • Clinical Translation: While for research use only, preclinical insights gained from Canagliflozin studies are informing the development of precision therapies for diabetes mellitus, diabetic nephropathy, and broader metabolic syndromes.

    As the scientific community pursues deeper understanding of glucose metabolism and renal physiology, Canagliflozin hemihydrate will remain a cornerstone for both foundational and applied research. Its pathway-specific action, validated in comparative studies like Breen et al. (2025), ensures that investigators can delineate SGLT2-mediated effects with confidence and reproducibility.

    References